The chronic kidney disease primary care practice.

C. Johnson

2008-05-01

North Carolina Medical Journal

Abstract:

What problem does this paper attempt to address?

Efficacy of Rigosertib, a Small Molecular RAS Signaling Disrupter for the Treatment of KRAS-mutant Colorectal Cancer

Xinyi Zhou,Qian Xiao,Dongliang Fu,Haochen Zhang,Yang Tang,Jinjie He,Yeting Hu,Xiangxing Kong,Fei Teng,Xiangrui Liu,Ying Yuan,Kefeng Ding

DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0532

2021-01-01

Cancer Biology and Medicine

Abstract:Objective: Mutant KRAS, the principal isoform of RAS, plays a pivotal role in the oncogenesis of colorectal cancer by constitutively activating the RAF/MEK/ERK and PI3K/AKT pathways. Effective targeted therapies are urgently needed. We investigated whether rigosertib, a benzyl styryl sulfone RAS signaling disruptor, could selectively kill KRAS-mutant colorectal cancer cells. Methods: CCK-8 was used to determine the cell viability. Patient-derived tumor and cancer cell xenograft models were used to detect the inhibitory efficacy of rigosertib. Flow cytometry was used to evaluate the apoptosis and cell cycle progression. Apoptosis and cell cycle arrest markers were detected by Western blot. DCFH-DA was used to determine the reactive oxygen species. Immunohistochemistry staining and Western blot were performed to characterize RAS signaling markers in colorectal cancer tissues and cells. Results: Rigosertib (RGS) exhibited a cytotoxic effect against colorectal cancer cells, which was greater in KRAS-mutant cells. Furthermore, RGS induced mitotic arrest and oxidative stress-dependent apoptosis in KRAS-mutant DLD1 and HCT116 cells. Besides, RGS disrupted RAS signaling, and the inhibition of RAS/MEK/ERK was independent of cellular oxidative stress. Using patient-derived xenograft models, the response and tumor inhibition of RGS were significantly higher in the KRAS-mutant subgroup, while p-MEK, p-ERK, and p-AKT levels of RGS-treated tumors were significantly decreased. Finally, in a KRAS-mutant, chemotherapy-resistant patient-derived xenograft model, RGS showed a stronger therapeutic effect than the combination standard therapy involving fluoropyrimidine + oxaliplatin/irinotecan + bevacizumab. Conclusions: These data showed that targeting RAS signaling using RGS could be a therapeutic treatment for KRAS-mutant colorectal cancer patients.
FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/β-catenin Signaling Pathway

Yanyan Chen,Xianping Rao,Kangmao Huang,Xiaoxia Jiang,Haohao Wang,Lisong Teng

DOI: https://doi.org/10.7150/jca.19273

IF: 3.9

2017-01-01

Journal of Cancer

Abstract:Aberrant Wnt/β-catenin pathway activation is frequently observed in human colorectal cancer (CRC) and has become a promising target for CRC treatment. Our study aimed to evaluate the effect of FH535, a small molecule inhibitor of Wnt/β-catenin pathway, on two colon cancer cell lines, HT29 and SW480. We found FH535 significantly inhibited colon cancer cell proliferation in vitro and induced cell cycle arrest. Moreover, FH535 inhibited colon cancer xenograft growth in vivo. Wound-healing assay and Transwell assay revealed that FH535 notably suppressed migration and invasion of SW480 cells. FH535 also repressed expression of cancer stem cell markers, CD24, CD44 and CD133 in HT29 cells. Real time-quantitative PCR and Western blotting revealed that targeting Wnt/β-catenin pathway using FH535 effectively downregulated target genes including cyclin D1 and survivin at mRNA and protein level, which contributed to the FH535-induced inhibitory effect on colon cancer cell proliferation. As mechanisms for suppressing cancer cell motility, FH535 downregulated expression of matrix metalloproteinase-7 and -9, Snail and vimentin. RNA sequencing revealed that FH535 prominently altered multiple biological pathways associated with DNA replication, cell cycle and metabolism. Our study highlights the anti-cancer effect of FH535 on colon cancer and presents its potential in colon cancer treatment.
Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer

Bo Fang,Yinshuang Lai,Hao Yan,Yue Ma,Zefeng Ni,Qianqian Zhu,Jianxia Zhang,Yanfei Ye,Mengying Wang,Peipei Wang,Yan Wang,Shuyuan Zhang,Min Hui,Dalong Wang,Yunjie Zhao,Xiaokun Li,Kun Wang,Zhiguo Liu

DOI: https://doi.org/10.1016/j.ejmech.2023.115703

IF: 7.088

2023-08-09

European Journal of Medicinal Chemistry

Abstract:Aberrant FGFR4 signaling has been implicated in the development of several cancers, making FGFR4 a promising target for cancer therapy. Several FGFR4-selective inhibitors have been developed, yet none of them have been approved. Herein, we report a novel series of 1,6-naphthyridine-2-one derivatives as potent and selective inhibitors targeting FGFR4 kinase. Preliminary structure-activity relationship analysis was conducted. The screening cascades revealed that 19g was the preferred compound among the prepared series. 19g demonstrated excellent kinase selectivity and substantial cytotoxic effect against all tested colorectal cancer cell lines. 19g induced significant tumor inhibition in a HCT116 xenograft mouse model without any apparent toxicity. Notably, 19g exhibited excellent potency in disrupting the phosphorylation of FGFR4 and downstream signaling proteins mediated by FGF18 and FGF19. Compound 19g might be a potential antitumor drug candidate for the treatment of colorectal cancer.

chemistry, medicinal
Targeting FGFR for cancer therapy

Pei Zhang,Lin Yue,QingQing Leng,Chen Chang,Cailing Gan,Tinghong Ye,Dan Cao

DOI: https://doi.org/10.1186/s13045-024-01558-1

IF: 28.5

2024-06-06

Journal of Hematology & Oncology

Abstract:The FGFR signaling pathway is integral to cellular activities, including proliferation, differentiation, and survival. Dysregulation of this pathway is implicated in numerous human cancers, positioning FGFR as a prominent therapeutic target. Here, we conduct a comprehensive review of the function, signaling pathways and abnormal alterations of FGFR, as well as its role in tumorigenesis and development. Additionally, we provide an in-depth analysis of pivotal phase 2 and 3 clinical trials evaluating the performance and safety of FGFR inhibitors in oncology, thereby shedding light on the current state of clinical research in this field. Then, we highlight four drugs that have been approved for marketing by the FDA, offering insights into their molecular mechanisms and clinical achievements. Our discussion encompasses the intricate landscape of FGFR-driven tumorigenesis, current techniques for pinpointing FGFR anomalies, and clinical experiences with FGFR inhibitor regimens. Furthermore, we discuss the inherent challenges of targeting the FGFR pathway, encompassing resistance mechanisms such as activation by gatekeeper mutations, alternative pathways, and potential adverse reactions. By synthesizing the current evidence, we underscore the potential of FGFR-centric therapies to enhance patient prognosis, while emphasizing the imperative need for continued research to surmount resistance and optimize treatment modalities.

oncology,hematology
Data from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in &Lt;i>braf</i>-Mutated Colorectal Cancers

Zhiyu Tang,Xia Yuan,Rong Du,Shing‐Hu Cheung,Guoliang Zhang,Jing Wei,Yuan Zhao,Feng Yue,Hao Peng,Zhong‐Xia Wang,Yunguang Du,Xiaoxia Hu,Wenfeng Gong,Yong Liu,Yajuan Gao,Ye Liu,Hongxing Rui,Shengjian Li,Shaohui Wang,Jiafu Ji,Lianhai Zhang,Shuangxi Li,D. Sutton,Wei Min,Changyou Zhou,Lai Wang,Lusong Luo

DOI: https://doi.org/10.1158/1535-7163.c.6538260

2023-01-01

Abstract:AbstractOncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAFV600E metastatic melanoma, their clinical efficacy in BRAFV600E colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAFV600E and EGFR mutation/amplification. In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAFV600E mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAFV600E mutation. Mol Cancer Ther; 14(10); 2187–97. ©2015 AACR.
Data from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in <i>BRAF</i>-Mutated Colorectal Cancers

Zhiyu Tang,Xi Yuan,Rong Du,Shing-Hu Cheung,Guoliang Zhang,Jing Wei,Yuan Zhao,Yingcai Feng,Hao Peng,Yi Zhang,Yunguang Du,Xiaoxia Hu,Wenfeng Gong,Yong Liu,Yajuan Gao,Ye Liu,Rui Hao,Shengjian Li,Shaohui Wang,Jiafu Ji,Lianhai Zhang,Shuangxi Li,David Sutton,Min Wei,Changyou Zhou,Lai Wang,Lusong Luo

DOI: https://doi.org/10.1158/1535-7163.c.6538260.v1

2023-01-01

Abstract:AbstractOncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAFV600E metastatic melanoma, their clinical efficacy in BRAFV600E colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAFV600E-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAFV600E and EGFR mutation/amplification. In BRAFV600E colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAFV600E mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAFV600E mutation. Mol Cancer Ther; 14(10); 2187–97. ©2015 AACR.
In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer

Maud Verstraete,Annelies Debucquoy,Annelies Gonnissen,Ruveyda Dok,Sofie Isebaert,Ellen Devos,William McBride,Karin Haustermans

DOI: https://doi.org/10.1186/s12885-015-2000-8

IF: 4.638

2015-12-01

BMC Cancer

Abstract:BackgroundWe examined the anti-tumor effect and radiosensitizing potential of a small molecule inhibitor of fibroblast growth factor receptor (FGFR) in colorectal cancer (CRC) in vitro and in vivo.MethodsEffects of in vitro drug treatment on cell survival, proliferation, FGFR signaling, cell cycle distribution, apoptosis and radiosensitivity were assessed using various CRC cell lines with FGFR wild type (Caco2 and HCA7) and FGFR2 amplification (HCT116, NCI-H716). In vivo tumor responses to FGFR inhibition with and without radiation therapy were evaluated by growth delay assays in two colorectal xenograft mouse models (NMRI nu/nu mice injected with NCI-H716 or CaCo2 cells). Mechanistic studies were conducted using Western blot analysis, immunohistochemistry and qPCR.ResultsIn the tested cell lines, the FGFR inhibitor (JNJ-42756493) was effective in vitro and in vivo in CRC tumors with highest expression of FGFR2 (NCI-H716). In vitro, cell proliferation in this line was decreased, associated with increased apoptotic death and decreased cell survival. In vivo, growth of NCI-H716 tumors was delayed by 5 days by drug treatment alone, although when drug delivery was stopped the relative tumor volume increased compared to control. The FGFR inhibitor did not radiosensitize NCI-H716 tumors either in vitro or in vivo.ConclusionsAmong tested CRC cell lines, the growth inhibitory activity of this FGFR inhibitor was evident in cell lines with high constitutive FGFR2 expression, suggesting that FGFR addiction may provide a window for therapeutic intervention, though caution is advised. Preclinical study with NCI-H716 and Caco2 tumor demonstrated that continued presence of drug could be essential for tumor growth control, especially in cells with aberrant FGFR expression. In the tested set-up, the inhibitor showed no radiosensitizing effect.

oncology
A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer

Ting Deng,Yibo Hou,Gaoyang Lin,Chunyan Feng,Kewei Liu,Wenke Chen,Wei Wei,Laiqiang Huang,Xiaoyong Dai

DOI: https://doi.org/10.3390/pharmaceutics15030944

IF: 6.525

2023-03-15

Pharmaceutics

Abstract:Colorectal cancer (CRC) is the leading cause of cancer-related deaths worldwide. Fibromodulin (FMOD) is the main proteoglycan that contributes to extracellular matrix (ECM) remodeling by binding to matrix molecules, thereby playing an essential role in tumor growth and metastasis. There are still no useful drugs that target FMOD for CRC treatment in clinics. Here, we first used public whole-genome expression datasets to analyze the expression level of FMOD in CRC and found that FMOD was upregulated in CRC and associated with poor patient prognosis. We then used the Ph.D.-12 phage display peptide library to obtain a novel FMOD antagonist peptide, named RP4, and tested its anti-cancer effects of RP4 in vitro and in vivo. These results showed that RP4 inhibited CRC cell growth and metastasis, and promoted apoptosis both in vitro and in vivo by binding to FMOD. In addition, RP4 treatment affected the CRC-associated immune microenvironment in a tumor model by promoting cytotoxic CD8+ T and NKT (natural killer T) cells and inhibiting CD25+ Foxp3+ Treg cells. Mechanistically, RP4 exerted anti-tumor effects by blocking the Akt and Wnt/β-catenin signaling pathways. This study implies that FMOD is a potential target for CRC treatment, and the novel FMOD antagonist peptide RP4 can be developed as a clinical drug for CRC treatment.

pharmacology & pharmacy
A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo

Jun Zeng,Kai Ran,Xinyue Li,Longyue Tao,Qiwei Wang,Jiangtao Ren,Rong Hu,Yongxia Zhu,Zhihao Liu,Luoting Yu

DOI: https://doi.org/10.3389/fphar.2022.998199

2022-09-21

Abstract:Gastric cancer (GC) is one of the most malignant cancers and is estimated to be fifth in incidence ratio and the third leading cause of cancer death worldwide. Despite advances in GC treatment, poor prognosis and low survival rate necessitate the development of novel treatment options. Fibroblast growth factor receptors (FGFRs) have been suggested to be potential targets for GC treatment. In this study, we report a novel selective FGFR inhibitor, RK-019, with a pyrido [1, 2-a] pyrimidinone skeleton. In vitro, RK-019 showed excellent FGFR1-4 inhibitory activities and strong anti-proliferative effects against FGFR2-amplification (FGFR2-amp) GC cells, including SNU-16 and KATO III cells. Treatment with RK-019 suppressed phosphorylation of FGFR and its downstream pathway proteins, such as FRS2, PLCγ, AKT, and Erk, resulting in cell cycle arrest and induction of apoptosis. Furthermore, daily oral administration of RK-019 could attenuate tumor xenograft growth with no adverse effects. Here, we reported a novel specific FGFR inhibitor, RK-019, with potent anti-FGFR2-amp GC activity both in vitro and in vivo.
BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

zhiyu tang,xi yuan,r du,shinghu cheung,guoliang zhang,jing wei,yuan zhao,yingcai feng,hao peng,yi zhang,yunguang du,xiaoxia hu,wenfeng gong,yajuan gao,ye liu,rui hao,shaohui wang,jiafu ji,lianhai zhang,shuangxi li,david sutton,min wei,changyou zhou,l wang,lusong luo

DOI: https://doi.org/10.1158/1535-7163.MCT-15-0262

2015-01-01

Molecular Cancer Therapeutics

Abstract:Oncogenic BRAF, which drives cell transformation and proliferation, has been detected in approximately 50% of human malignant melanomas and 5% to 15% of colorectal cancers. Despite the remarkable clinical activities achieved by vemurafenib and dabrafenib in treating BRAF(V600E) metastatic melanoma, their clinical efficacy in BRAF(V600E) colorectal cancer is far less impressive. Prior studies suggested that feedback activation of EGFR and MAPK signaling upon BRAF inhibition might contribute to the relative unresponsiveness of colorectal cancer to the first-generation BRAF inhibitors. Here, we report characterization of a dual RAF kinase/EGFR inhibitor, BGB-283, which is currently under clinical investigation. In vitro, BGB-283 potently inhibits BRAF(V600E)-activated ERK phosphorylation and cell proliferation. It demonstrates selective cytotoxicity and preferentially inhibits proliferation of cancer cells harboring BRAF(V600E) and EGFR mutation/amplification. In BRAF(V600E) colorectal cancer cell lines, BGB-283 effectively inhibits the reactivation of EGFR and EGFR-mediated cell proliferation. In vivo, BGB-283 treatment leads to dose-dependent tumor growth inhibition accompanied by partial and complete tumor regressions in both cell line-derived and primary human colorectal tumor xenografts bearing BRAF(V600E) mutation. These findings support BGB-283 as a potent antitumor drug candidate with clinical potential for treating colorectal cancer harboring BRAF(V600E) mutation. (C) 2015 AACR.
FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Shike Yan,Bing Zhang,Jingwen Feng,Haigang Wu,Namin Duan,Yamin Zhu,Yueliang Zhao,Shuang Shen,Kai Zhang,Wenhui Wu,Ning Liu

DOI: https://doi.org/10.3389/fphar.2021.764699

IF: 5.6

2022-01-19

Frontiers in Pharmacology

Abstract:Non-small cell lung cancer (NSCLC) is one of the most common malignancies in the world. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) have been used as a first-line treatment for patients harboring with EGFR mutations in advanced NSCLC. Nevertheless, the drug resistance after continuous and long-term chemotherapies considerably limits its clinical efficacy. Therefore, it is of great importance to develop new chemotherapeutic agents and treatment strategies to conquer the drug resistance. FGFC1 (Fungi fibrinolytic compound 1), a type of bisindole alkaloid from a metabolite of the rare marine fungi Starchbotrys longispora. FG216, has exhibited excellent fibrinolytic and anti-inflammatory activity. However, the potent efficacy of FGFC1 in human cancer therapy requires further study. Herein, we demonstrated that FGFC1 selectively suppressed the growth of NSCLC cells with EGFR mutation. Mechanistically, FGFC1 treatment significantly induced the apoptosis of erlotinib-resistant NSCLC cells H1975 in a dose-dependent manner, which was proved to be mediated by mitochondrial dysfunction and elevated accumulation of intracellular reactive oxygen species (ROS). Scavenging ROS not only alleviated FGFC1-induced apoptosis but also relieved the decrease of phospho-Akt. We further confirmed that FGFC1 significantly decreased the phosphorylation of protein EGFR, phosphatidylinositol 3-kinase (PI3K), protein kinase B (Akt), and mammalian target of rapamycin (mTOR) in H1975 cells. Notably, PI3K inhibitor (LY294002) could promote the accumulation of ROS and the expression levels of apoptosis-related proteins induced by FGFC1. Molecular dynamics simulations indicated that FGFC1 can inhibit EGFR and its downstream PI3K/Akt/mTOR pathway through directly binding to EGFR, which displayed a much higher binding affinity to EGFR T790M/L858R than EGFR WT . Additionally, FGFC1 treatment also inhibited the migration and invasion of H1975 cells. Finally, FGFC1 effectively inhibited tumor growth in the nude mice xenograft model of NSCLC. Taken together, our results indicate that FGFC1 may be a potential candidate for erlotinib-resistant NSCLC therapy.

pharmacology & pharmacy
Fibroblast growth factor receptor risk signature predicts patient prognosis and immunotherapy resistance in colorectal cancer

Xiaofang Li,Zhiling Pan,Tiankuo Luan,Qian Xiao,Liuying Li,Qianxue Wu,Guoqing Yao,Xiang Zhang,Daqiang Song

DOI: https://doi.org/10.3389/fimmu.2024.1493673

IF: 7.3

2024-11-29

Frontiers in Immunology

Abstract:Background: Fibroblast Growth Factor Receptor (FGFR) signaling is linked with tumor progression and tumor immunoevasion, yet the potential effect of FGFR signature on the prognosis of patient with colorectal cancer (CRC) and response to immune therapy remains elusive. Methods: The fibroblast growth factor receptor risk signature (FRS) was identified through single-cell RNA sequencing, bulk RNA sequencing, and machine learning techniques. Signaling enrichment analyses were conducted using Gene Set Enrichment Analysis (GSEA) and the Kyoto Encyclopedia of Genes and Genomes (KEGG). Drugs targeting the FRS were predicted using the Cancer Therapeutics Response Portal (CTRP) and PRISM databases. The analysis of T cell function and the tumor microenvironment (TME) was performed using flow cytometry. Results: In this study, we characterized the FRS in cancer patients with CRC. By integrating advanced techniques, we identified the FRS and revealed the intricate molecular landscape and diversity of the FRS within the TME. Notably, the FRS effectively predicted unfavorable prognosis and resistance to immunotherapy in CRC patients. Furthermore, PHA-793887, identified as a potential FRS inhibitor by the CTRP and PRISM databases, significantly restructured the immunosuppressive TME and enhanced the antitumor immune response, resulting in a reduced tumor burden in the MC38 murine tumor model. Conclusion: Together, these data support FRS positively correlates with poor prognosis and therapy resistance. The PHA-793887 could be a potential FRS inhibitor to improving the effectiveness of CRC management via bolstering antitumor immunity.

immunology
Abstract 643: Analysis of the effect of FGFR inhibitor and cannabidiol in colorectal cancer

Yeonuk Ju,Wooyoung Kim,Bugyeom Kim,Jiyoung Kim,Junwoo Bong,Chinock Cheong,Sanghee Kang,Byung Wook Min,Sang Cheul Oh,Sun Il Lee

DOI: https://doi.org/10.1158/1538-7445.am2024-643

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Introduction: Colorectal cancer (CRC) remains a serious health problem worldwide. In particular, in the case of stage 4 metastatic cancer, a cure can be expected as multidisciplinary treatment is possible by combining surgery, chemotherapy, and the development of targeted anticancer drugs, but there is still no type of treatment available. It is limited. FGFR (Fibroblast Growth Factor Receptor) has emerged as an important anticancer target in various malignant tumors, and small molecule-based targeted treatments have been developed and clinical trials are underway, and some colon cancer patients are known to have FGFR genetic alterations. Cannabidiol (CBD), a non-psychoactive cannabinoid, has recently been reported to be associated with the ability to induce cell death through various signaling systems in colon cancer, and has anticancer effects and mechanisms related to overcoming anticancer drug resistance. has been identified. Therefore, we sought to analyze the effect of FGFR inhibitors on colon cancer, explore the possibility of developing them as new target substances, and find ways to increase anticancer effects by confirming the effects of combination with cannabidiol (CBD) and related mechanisms. Method: Cell survival was confirmed through the WST-1 assay, an assay for measuring cell viability. The signaling pathway was identified through western blot. Data were compared using two-tailed Student’s t-test or one-way analysis of variance and Tukey’s post hoc test. Result: The FGFR expression pattern was confirmed in various cancer cell lines, and NCI-H716 was confirmed to have high FGFR2 expression in the colorectal cancer cell line. (Figure 1) As a result of treating CBD 4uM and AZD 10nM (Cell proliferation, apoptosis, western blot), cell death occurred more clearly when treated together than when treated alone, confirming the effectiveness of the combination. (Figure 2) An increase in apoptosis of NCI-H716 cells was confirmed when CBD and AZD 4547 were combined. (Figure 3) Through a heatmap of differentially expressed genes in RNA sequencing, it was estimated that ER stress may be related to the combination effect. (Figure 4) The relationship between ER stress and the combination of CBD and AZD 4547 on apoptosis of NCI-H716 cells was confirmed. (Figure 5) Conclusion: It was confirmed that the combined effect of FGFR inhibitor and cannabidiol was effective in colorectal cancer cells, and it was assumed to be related to the ER stress pathway. Citation Format: Yeonuk Ju, Wooyoung Kim, Bugyeom Kim, Jiyoung Kim, Junwoo Bong, Chinock Cheong, Sanghee Kang, Byung Wook Min, Sang Cheul Oh, Sun Il Lee. Analysis of the effect of FGFR inhibitor and cannabidiol in colorectal cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 643.

oncology
FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells

Jingwen Feng,Songlin Li,Bing Zhang,Namin Duan,Rui Zhou,Shike Yan,Jeevithan Elango,Ning Liu,Wenhui Wu

DOI: https://doi.org/10.3390/md20010076

2022-01-17

Marine Drugs

Abstract:FGFC1, an active compound isolated from the culture of marine fungi Stachybotrys longispora FG216, elicits fibrinolytic, anti-oxidative, and anti-inflammatory activity. We have previously reported that FGFC1 inhibited the proliferation, migration, and invasion of the non-small cell lung cancer (NSCLC) cells in vitro. However, the precise mechanisms of FGFC1 on NSCLC and its anti-cancer activity in vivo remains unclear. Hence, this study was focused to investigate the effects and regulatory mechanisms of FGFC1 on two NSCLC cell lines, EGFR-mutant PC9 (ex19del) and EGFR wild-type H1299. Results suggested that FGFC1 significantly inhibited proliferation, colony formation, as well as triggered G0/G1 arrest and apoptosis of PC9 cells in a dose- and time-dependent manner, but no obvious inhibitory effects were observed in H1299 cells. Subsequently, transcriptome analysis revealed that FGFC1 significantly down-regulated 28 genes related to the NF-κB pathway, including IL-6, TNF-α, and ICAM-1 in the PC9 cells. We further confirmed that FGFC1 decreased the expression of protein p-IKKα/β, p-p65, p-IκB, IL-6, and TNF-α. Moreover, NF-κB inhibitor PDTC could strengthen the effects of FGFC1 on the expression of CDK4, Cyclin D1, cleaved-PARP-1, and cleaved-caspase-3 proteins, suggesting that the NF-κB pathway plays a major role in FGFC1-induced cell cycle arrest and apoptosis. Correspondingly, the nuclear translocation of p-p65 was also suppressed by FGFC1 in PC9 cells. Finally, the intraperitoneal injection of FGFC1 remarkably inhibited PC9 xenograft growth and decreased the expression of Ki-67, p-p65, IL-6, and TNF-α in tumors. Our results indicated that FGFC1 exerted anti-cancer activity in PC9 cells via inhibiting the NF-κB signaling pathway, providing a possibility for FGFC1 to be used as a lead compound for the treatment of NSCLC in the future.

pharmacology & pharmacy,chemistry, medicinal
Anti-Allergic Drug Azelastine Suppresses Colon Tumorigenesis By Directly Targeting Arf1 To Inhibit Iqgap1-Erk-Drp1-Mediated Mitochondrial Fission

Hui-Fang Hu,Wen Wen Xu,Yang-Jia Li,Yan He,Wei-Xia Zhang,Long Liao,Qi-Hua Zhang,Lei Han,Xing-Feng Yin,Xiao-Xu Zhao,Yun-Long Pan,Bin Li,Qing-Yu He

DOI: https://doi.org/10.7150/thno.48698

IF: 11.6

2021-01-01

Theranostics

Abstract:This study aimed to screen novel anticancer strategies from FDA-approved non-cancer drugs and identify potential biomarkers and therapeutic targets for colorectal cancer (CRC).Methods: A library consisting of 1056 FDA-approved drugs was screened for anticancer agents. WST-1, colony-formation, flow cytometry, and tumor xenograft assays were used to determine the anticancer effect of azelastine. Quantitative proteomics, confocal imaging, Western blotting and JC-1 assays were performed to examine the effects on mitochondrial pathways. The target protein of azelastine was analyzed and confirmed by DARTS, WST-1, Biacore and tumor xenograft assays. Immunohistochemistry, gain- and loss-of-function experiments, WST-1, colony-formation, immunoprecipitation, and tumor xenograft assays were used to examine the functional and clinical significance of ARF1 in colon tumorigenesis.Results: Azelastine, a current anti-allergic drug, was found to exert a significant inhibitory effect on CRC cell proliferation in vitro and in vivo, but not on ARF1-deficient or ARF1-T48S mutant cells. ARF1 was identified as a direct target of azelastine. High ARF1 expression was associated with advanced stages and poor survival of CRC. ARF1 promoted colon tumorigenesis through its interaction with IQGAP1 and subsequent activation of ERK signaling and mitochondrial fission by enhancing the interaction of IQGAP1 with MEK and ERK. Mechanistically, azelastine bound to Thr-48 in ARF1 and repressed its activity, decreasing Drp1 phosphorylation. This, in turn, inhibited mitochondrial fission and suppressed colon tumorigenesis by blocking IQGAP1-ERK signaling.Conclusions: This study provides the first evidence that azelastine may be novel therapeutics for CRC treatment. ARF1 promotes colon tumorigenesis, representing a promising biomarker and therapeutic target in CRC.
Antitumor Effect of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient Derived Xenograft Mouse Model Endogenously Expressing an FGFR2-CCDC6 Fusion Protein.

Yu Wang,Xiwei Ding,Shaoqing Wang,Catherine D. Moser,Hassan M. Shaleh,Essa A. Mohamed,Roongruedee Chaiteerakij,Loretta K. Allotey,Gang Chen,Katsuyuki Miyabe,Melissa S. McNulty,Albert Ndzengue,Emily G. Barr Fritcher,Ryan A. Knudson,Patricia T. Greipp,Karl J. Clark,Michael S. Torbenson,Benjamin R. Kipp,Jie Zhou,Michael T. Barrett,Michael P. Gustafson,Steven R. Alberts,Mitesh J. Borad,Lewis R. Roberts

DOI: https://doi.org/10.1016/j.canlet.2016.05.017

IF: 9.756

2016-01-01

Cancer Letters

Abstract:Cholangiocarcinoma is a highly lethal cancer with limited therapeutic options. Recent genomic analysis of cholangiocarcinoma has revealed the presence of fibroblast growth factor receptor 2 (FGFR2) fusion proteins in up to 13% of intrahepatic cholangiocarcinoma (iCCA). FGFR fusions have been identified as a novel oncogenic and druggable target in a number of cancers. In this study, we established a novel cholangiocarcinoma patient derived xenograft (PDX) mouse model bearing an FGFR2-CCDC6 fusion protein from a metastatic lung nodule of an iCCA patient. Using this PDX model, we confirmed the ability of the FGFR inhibitors, ponatinib, dovitinib and BGJ398, to modulate FGFR signaling, inhibit cell proliferation and induce cell apoptosis in cholangiocarcinoma tumors harboring FGFR2 fusions. In addition, BGJ398 appeared to be superior in potency to ponatinib and dovitinib in this model. Our findings provide a strong rationale for the investigation of FGFR inhibitors, particularly BGJ398, as a therapeutic option for cholangiocarcinoma patients harboring FGFR2 fusions. (C) 2016 Elsevier Ireland Ltd. All rights reserved.
Molecular force probe measurement of antigen I/II-matrix protein interactions.

M. Soell,J. Hemmerlé,M. Hannig,Y. Haïkel,H. Sano,D. Selimović

DOI: https://doi.org/10.1111/j.1600-0722.2010.00785.x

2010-12-01

European Journal Of Oral Sciences

Abstract:Viridans streptococci possess a family of immunologically and structurally related cell-surface proteins, termed antigen I/II, which may function as adhesins and enable oral streptococci to adhere to saliva-coated surfaces and matrix proteins. Here we used atomic force microscopy in the molecular force mode to measure the specific interaction forces between antigen I/II and two matrix proteins, collagen and fibronectin. These matrix proteins provide important binding sites for adherence of oral streptococcal in dentinal caries and endocarditis, respectively. Antigen I/II-coated cantilever tips were brought into contact with collagen- or fibronectin-coated silica coverslips. For the protein I/II-fibronectin interaction experiments, the mean strength of the last ruptures was 216 pN, with most of the detachments located around 125 pN. In antigen I/II-collagen interaction experiments, the mean strength of the last rupture forces corresponded to 136 pN, with the most frequent unbinding force around 75 pN. Thus, our findings definitely suggest that, under the present experimental conditions, antigen I/II binds more strongly to fibronectin than to type I collagen. This might be of relevance for the attachment of viridians streptococci to surfaces exposed to strong hydrodynamic shearing forces under in vivo conditions.
Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers

Shuang Liu,Junfen Shi,Chang Lu,Miao Zhang,Ying Xin,Yan Zhu,Jijun Li,Hong Luo,Yinghui Sun

DOI: https://doi.org/10.1158/1538-7445.am2024-1928

IF: 11.2

2024-03-22

Cancer Research

Abstract:Abstract Despite the pivotal role of KRAS G12C in tumor initiation and progression, currently available KRAS G12C inhibitors have relatively modest activity compared to other approved therapies targeting other classic oncogenic drivers. Fortunately, efforts to improve the anti-tumor response to KRAS G12C targeted therapy have benefited from the use of combination approaches. Here, we found that treatment with KRAS G12C inhibitors induces sustained activation of focal adhesion kinase (FAK) in KRAS G12C mutant cell lines from various cancer types, including non-small cell lung cancer, colorectal cancer, and pancreatic cancer. These results suggest a potential role for FAK in adaptive resistance to KRAS G12C inhibition and encourage us to explore the anticancer effects of combining the KRAS G12C inhibitor SY-5933 with a FAK inhibitor, CT-707. The cell viability and clonogenic assays using various KRAS G12C mutant cancer cell lines showed that the combination of SY-5933 and CT-707 synergistically inhibited cell growth. Mechanistically, this enhanced anti-proliferative effect is associated with a significant decrease in FAK activity and a more pronounced induction of cell cycle arrest and apoptosis. In vivo efficacy studies in multiple cell line derived xenograft (CDX) models, the combination of SY-5933 plus CT-707 consistently induced a more potent anti-tumor response than either monotherapy alone. In conclusion, our results demonstrate that CT-707 has the potential to enhance the efficacy of SY-5933 by suppressing adaptive FAK activation under KRAS G12C inhibition. This provides a rationale for an innovative combination therapy to improve outcomes in patients with KRAS G12C mutated cancers. Citation Format: Shuang Liu, Junfen Shi, Chang Lu, Miao Zhang, Ying Xin, Yan Zhu, Jijun Li, Hong Luo, Yinghui Sun. Targeting FAK to improve the therapy of KRAS G12C mutant cancers [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 1928.

oncology
FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer

Yiming Li,Yongkang Shi,Xiuyuan Zhang,Piao Li,Li Ma,Pengbo Hu,Liang Xu,Yuhong Dai,Shu Xia,Hong Qiu

DOI: https://doi.org/10.1016/j.bbadis.2023.166665

Abstract:Fibroblast growth factor receptor 2 (FGFR2) is frequently activated by overexpression or mutation, and an abnormal fibroblast growth factor (FGF)/FGFR signaling pathway is associated with the occurrence, development, and poor prognosis of colorectal cancer (CRC). Our preliminary analysis found that plasminogen activator inhibitor-1 (PAI-1) expression may be related to FGF/FGFR signaling, however, their role in the tumor immune microenvironment remains unclear. In this study, we observed markedly higher PAI-1 expression in CRC patients with poor survival rates. PAI-1 is regulated by FGF/FGFR2 in colon cancer cells and is involved in M2 macrophage polarization. Mechanistically, inhibiting the JAK2/STAT3 signaling pathway could cause PAI-1 downregulation. Furthermore, the activation of phosphorylated STAT3 upregulated PAI-1. In vivo, FGFR2 overexpression in tumor-bearing mouse models suggested that a PAI-1 inhibitor could rescue FGFR2/PAI-1 axis-induced M2 macrophage polarization, which leads to effective immune activity and tumor suppression. Moreover, the combination of a PAI-1 inhibitor and anti-PD-1 therapy exhibited superior antitumor activity in mice. These findings offer novel insights into the molecular mechanisms underlying tumor deterioration and provide potential therapeutic targets for CRC treatment.
A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity.

Ying Kong,Xinyue Zhao,Zhaofu Wang,Siqi Yuan,Sheng Chen,Shidi Lou,Shichao Ma,Yunfeng Li,Xinghao Wang,Yangfeng Ge,Guobin Li,Hongbing Yang,Mengxi Zhao,Dandan Li,Hailong Zhang,Wenfu Tan,Juan Wang

DOI: https://doi.org/10.1158/1535-7163.MCT-23-0719

2024-01-01

Molecular Cancer Therapeutics

Abstract:The aberrant activation of FGFR acts as a potent driver of multiple types of human cancers. Despite the development of several conventional small-molecular FGFR inhibitors, their clinical efficacy is largely compromised because of low selectivity and side effects. In this study, we report the selective FGFR1/2-targeting proteolysis-targeting chimera BR-cpd7 that displays significant isoform specificity to FGFR1/2 with half maximal degradation concentration values around 10 nmol/L while sparing FGFR3. The following mechanistic investigation reveals the reduced FGFR signaling, through which BR-cpd7 induces cell-cycle arrest and consequently blocks the proliferation of multiple FGFR1/2-dependent tumor cells. Importantly, BR-cpd7 has almost no antiproliferative activity against cancer cells without FGFR aberrations, furtherly supporting its selectivity. In vivo, BR-cpd7 exhibits robust antitumor effects in FGFR1-dependent lung cancer at well-tolerated dose schedules, accompanied by complete FGFR1 depletion. Overall, we identify BR-cpd7 as a promising candidate for developing a selective FGFR1/2-targeted agent, thereby offering a new therapeutic strategy for human cancers in which FGFR1/2 plays a critical role.

The chronic kidney disease primary care practice.

Efficacy of Rigosertib, a Small Molecular RAS Signaling Disrupter for the Treatment of KRAS-mutant Colorectal Cancer

FH535 Inhibits Proliferation and Motility of Colon Cancer Cells by Targeting Wnt/β-catenin Signaling Pathway

Design, synthesis, and biological evaluation of 1,6-naphthyridine-2-one derivatives as novel FGFR4 inhibitors for the treatment of colorectal cancer

Targeting FGFR for cancer therapy

Data from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in &Lt;i&gt;braf&lt;/i&gt;-Mutated Colorectal Cancers

Data from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in <i>BRAF</i>-Mutated Colorectal Cancers

In vitro and in vivo evaluation of the radiosensitizing effect of a selective FGFR inhibitor (JNJ-42756493) for rectal cancer

A Novel Fibromodulin Antagonist Peptide RP4 Exerts Antitumor Effects on Colorectal Cancer

A novel small molecule RK-019 inhibits FGFR2-amplification gastric cancer cell proliferation and induces apoptosis in vitro and in vivo

BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers

FGFC1 Selectively Inhibits Erlotinib-Resistant Non-Small Cell Lung Cancer via Elevation of ROS Mediated by the EGFR/PI3K/Akt/mTOR Pathway

Fibroblast growth factor receptor risk signature predicts patient prognosis and immunotherapy resistance in colorectal cancer

Abstract 643: Analysis of the effect of FGFR inhibitor and cannabidiol in colorectal cancer

FGFC1 Exhibits Anti-Cancer Activity via Inhibiting NF-κB Signaling Pathway in EGFR-Mutant NSCLC Cells

Anti-Allergic Drug Azelastine Suppresses Colon Tumorigenesis By Directly Targeting Arf1 To Inhibit Iqgap1-Erk-Drp1-Mediated Mitochondrial Fission

Antitumor Effect of FGFR Inhibitors on a Novel Cholangiocarcinoma Patient Derived Xenograft Mouse Model Endogenously Expressing an FGFR2-CCDC6 Fusion Protein.

Molecular force probe measurement of antigen I/II-matrix protein interactions.

Abstract 1928: Targeting FAK to improve the therapy of KRAS G12C mutant cancers

FGFR2 upregulates PAI-1 via JAK2/STAT3 signaling to induce M2 polarization of macrophages in colorectal cancer

A Selective FGFR1/2 PROTAC Degrader with Antitumor Activity.

Data from BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in &Lt;i>braf</i>-Mutated Colorectal Cancers